SCHEDULE: Deep Track Capital Discloses 9.99% Stake in Palisade Bio

Sentiment:

Beneficial Ownership Report (Schedule 13G) 8 October 2025 4:05 PM

Deep Track Capital and its affiliates have reported a 9.99% beneficial ownership stake in Palisade Bio, Inc. common stock.

Capital raiseThe beneficial ownership includes 6,428,571 Pre-Funded Warrants exercisable into common shares, which, along with a reference to the issuer's Prospectus filed on October 2, 2025, suggests a recent capital raise involving these warrants.

Summary

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., David Kroin, and Deep Track Special Opportunities Fund, LP collectively reported beneficial ownership of Palisade Bio, Inc. common stock.
Deep Track Capital, LP and David Kroin each beneficially own 10,012,958 shares, representing 9.99% of the class.
Deep Track Biotechnology Master Fund, Ltd. beneficially owns 6,509,387 shares, representing 6.49% of the class.
Deep Track Special Opportunities Fund, LP beneficially owns 3,503,571 shares, representing 3.5% of the class.
The total shares used for percentage calculation are 100,229,818, based on 96,645,431 common stock outstanding as of October 2, 2025, and 3,584,387 convertible common stock.
Beneficially owned shares include 6,428,571 Pre-Funded Warrants exercisable into common shares, subject to a 9.99% Maximum Percentage exercise limitation.

Sentiment

Score: 5

Explanation: The filing is a factual report of beneficial ownership and does not contain qualitative statements that would indicate a positive or negative sentiment.

Future Outlook

Industry Context

Stakeholder Impact

Increased institutional ownership by Deep Track Capital and its affiliates may signal increased investor confidence in Palisade Bio, potentially influencing other investors and market perception.

Key Dates

Date	Description
2025-10-01	Date of event requiring filing of this statement
2025-10-02	Date of issuer's Prospectus filing with SEC, stating 96,645,431 common stock outstanding
2025-10-08	Filing date of Schedule 13G

Recommendation

hold

The filing indicates a significant beneficial ownership stake by a prominent institutional investor, Deep Track Capital, which can be interpreted as a vote of confidence. However, a Schedule 13G filing primarily reports ownership and does not provide sufficient operational or financial details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further financial disclosures or strategic updates from Palisade Bio, while acknowledging the positive signal of institutional interest.

Keywords

Palisade Bio, Deep Track Capital, Beneficial Ownership, Schedule 13G, Common Stock, Pre-Funded Warrants, Institutional Investor, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.